Trial · NCT07443592
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592, Not applicable, Not yet recruiting, PETHEMA Foundation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment for Ph-negative ALL for Adults up to 65 Years. Trials, record NCT07443592. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07443592
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment for Ph-negative ALL for Adults up to 65 Years
- NCT number
- NCT07443592
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 330 participants, estimated
- Lead sponsor
- PETHEMA Foundation
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL), Transplantation
- First posted
- 2026-03-02
- Last updated
- 2026-03-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival comparison versus previous trial | 5 years | Comparison of time from diagnosis to death or last follow-up between the present LAL-2025 trial and the previous LAL19 trial for adult Ph-negative |
| Secondary | Complete remission (CR) rate | 4 or 8 weeks after treatment onset | Proportion of participants who achieve CR with or 2 induction therapy lines |
| Secondary | MRD status after induction and consolidation | After induction (4-8 weeks) and consolidation (16-20 weeks) | Proportion of participants who achieve and maintain the negative MRD status (\<10-4) |
| Secondary | MRD variation between induction and after cycle 1 blinatumomab | After induction (4-8 weeks) and after cycle 1 blinatumomab (8-12 weeks) | Proportion of B-cell precursor ALL participants who achieve and maintain the negative MRD status (\<10-4) at week 4 or 8 (end of induction 1 or 2) and after week 8 or 12 (after blinatumomab cycle1) |
| Secondary | Frequency of allogeneic stem cell transplantation (alloSCT) dut to high-risk genetics | 5 years | Proportion of participants that are allocated to alloSCT exclusively due to the presence to high-risk genetic alterations defined in the trial |
| Secondary | Effect of blinatumomab within each B-cell precursor ALL genetic subtype | 5 years | Proportion of paarticipants with negative MRD status within each B-cell precursor ALL genetic subtype according to the World Health Organization (WHO) and the International Consensus Classification of Acute Leukemia (ICC) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07443592
GET https://conductscience.org/api/trials/v1/NCT07443592/registered